Skip to main content
Loading...
Menu social network
LinkedIn
Facebook
X
Youtube
Menu top
Assistance
User account menu
Log in
Main navigation
Home
Programme
Download the app
App
Download the app
App
Menu
Login
Close
Main navigation mobile
Home
Programme
Menu top
Assistance
Menu social network
LinkedIn
Facebook
X
Youtube
34 results
D1.16 - Molecular sensitization profiles in house dust mite allergic patients from Valencian Community
D1.18 - Comparative Analysis of Nasal Secretions and Serum Biomarkers in House Dust Mite Allergy: Correlation with Symptoms and Skin Prick Test Results
D1.19 - Contribution of Panallergens to Edible Insect Reactivity in Mite-Sensitized Individuals
D1.20 - Progesterone-Induced Urticaria: Diagnostic and Therapeutic Approach
D1.22 - Molecular Allergen Sensitization Patterns in Cat, Dog and Horse Allergies in Children
D1.23 - Unrestricted Potential: The Role of AMS in Tackling Allergy Labels
D1.24 - Towards risk assessment of peanut sensitised patients based on statistical modelling of 32,500 IgE-macroarray test results
D1.25 - Clinical Characteristics of Chronic Urticaria in Adults Under 45 Years Old with Vitamin D Insufficiency
D2.332 - Patients With HAE Report Positive Perceptions Following Berotralstat Treatment: Results from a Focus Group
D2.325 - Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study
D2.326 - Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study
D2.327 - Outcome of hematopoietic stem cells transplantation for inborn error of immunity in Vietnam
D2.328 - Comparison of the frequency of viral infections in immunocompromised patients receiving immunoglobulin by different routes
D2.329 - Impact of Berotralstat on Quality of Life among Patients with Hereditary Angioedema: Pooled Analysis of the APeX-2 and APeX-J Trials
D2.330 - Hereditary angioedema prophylaxis therapy: berotralstat and lanadelumab safety profile
D2.331 - Lanadelumab safety and efficacy in patients aged ≥12 with hereditary angioedema (HAE) in China for long-term prophylaxis (LTP): An open-label, multicenter study
D2.334 - Real-World Effectiveness of Lanadelumab in Hereditary Angioedema: A 12-Month Retrospective Study at a Single Center in Colombia
D2.336 - Evolution of Hereditary Angioedema Prophylaxis in Hungary Over Four Decades (1979-2023)
D2.338 - The Effect of Covid-19 Vaccines on Adult Primary Immunodeficiency Patients
D2.339 - Hereditary Angioedema Burden: Impact on Quality of Life, Disease Management, and Sleep Health
Pagination
Current page
1
Page
2
Next page
Next
Last page
Last
Download the app
The congress at your fingertips
Available on
Download